HRMY
Harmony Biosciences Holdings, Inc.
Key Financials
Net Income
$158.7M
↑ 9.1%
Gross Profit
$670.1M
↑ 20.1%
Revenue
$868.5M
↑ 21.5%
Operating Income
$208.5M
↑ 9.2%
EPS (Diluted)
$2.71
↑ 8.0%
Total Liabilities
$401.4M
↑ 18.0%
Cash & Equivalents
$752.5M
↑ 66.1%
Total Assets
$1.3B
↑ 27.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 144 | 7/2/2026 | View on SEC |
| 144 | 6/30/2026 | View on SEC |
| 144 | 6/26/2026 | View on SEC |
| 144 | 6/24/2026 | View on SEC |
| 144 | 6/9/2026 | View on SEC |
| 144 | 6/5/2026 | View on SEC |
| 144 | 6/4/2026 | View on SEC |
| 4 | 5/18/2026 | View on SEC |
| 3 | 5/18/2026 | View on SEC |
| 4 | 5/18/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | HRMY |
| Company Name | Harmony Biosciences Holdings, Inc. |
| CIK | 1802665 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (484) 539-9800 |